XBIvsARKGETF Comparison
VS
State Street SPDR S&P Biotech ETF (XBI) belongs to the US Health Care segment. ARK Genomic Revolution ETF (ARKG) is part of the BioTech & Genomics segment. XBI's top 2 sector exposures are Healthcare and Finance. In contrast, ARKG's top sector exposures are Healthcare. XBI is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.75% for ARKG. XBI is up 34.48% year-to-date (YTD) with +$925M in YTD flows. ARKG performs better with 61.37% YTD performance, and +$141M in YTD flows. Run a side-by-side ETF comparison of XBI and ARKG below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XBI vs ARKG performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/04/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XBI ARKG | +7.89%+15.64% | +22.96%+29.82% | +34.48%+61.37% | +76.10%+89.16% | +107.25%+47.27% | +23.60%-44.77% |
| Flows | XBI ARKG | +$725M+$106M | +$1.19B+$226M | +$925M+$141M | +$1.79B+$143M | +$130M-$436M | +$1.57B-$2.19B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XBI ARKG | +30.41%+46.19% | +27.90%+44.31% | +28.23%+43.94% | +32.90%+46.38% |
| Max drawdown | XBI ARKG | -10.46%-13.89% | -10.46%-27.52% | -32.94%-46.41% | -53.28%-78.50% |
| Max drawdown duration | XBI ARKG | 40d32d | 40d126d | 331d882d | 1622d1823d |
Trading data
XBI | ARKG | |
Last sale 9/4/2026 at 1:30 PM | $163.81 | $47.14 |
| Previous close 09/04/2026 | $164.38 | $47.20 |
| Consolidated volume 09/04/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
ARKG
is actively managed and doesn’t replicate an indexXBI | ARKG | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/4/2026 at 1:30 PM
Live
Closed
XBI | ARKG | |
|---|---|---|
| Last price | $163.81 | $47.14 |
| 1D performance | -0.35% | -0.13% |
| AuM | $11.43 B | $2.00 B |
| E/R | 0.35% | 0.75% |
Characteristics
XBI | ARKG | |
|---|---|---|
| Management strategy | Passive | Active |
| Provider | State Street Investment Management | Ark Investment |
| Benchmark | S&P Biotechnology Select Industry Index | - |
| N° of holdings | 149 | 31 |
| Asset class | Equities | - |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 31, 2006 | April 2, 2019 |
| ESG | No | No |
Advertisement
Exposure
Countries
XBI
USA
95.3%
Other
4.7%
ARKG
USA
88.43%
Other
11.57%
Sectors
XBI
Healthcare
99.41%
Other
0.59%
ARKG
Healthcare
97.99%
Other
2.01%
Advertisement
Diversification
XBI
Total weight of top 15 holdings out of 15
20.29%
ARKG
Total weight of top 15 holdings out of 15
75.55%
Top 15 holdings
Data as of July 31, 2026
XBI
Apogee Therapeutics, Inc.
1.65%
Oruka Therapeutics, Inc.
1.53%
Dianthus Therapeutics, Inc.
1.42%
Erasca, Inc.
1.38%
Twist Bioscience Corp.
1.37%
Kymera Therapeutics, Inc.
1.34%
Spyre Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.32%
CG Oncology, Inc.
1.32%
Protagonist Therapeutics, Inc.
1.31%
Praxis Precision Medicines, Inc.
1.30%
Regeneron Pharmaceuticals, Inc.
1.29%
Cogent Biosciences, Inc.
1.26%
Natera, Inc.
1.26%
Arrowhead Pharmaceuticals, Inc.
1.22%
ARKG
10X Genomics, Inc.
9.41%
Twist Bioscience Corp.
7.74%
Tempus AI, Inc.
6.57%
CRISPR Therapeutics AG
6.30%
Personalis, Inc.
5.48%
Absci Corp.
5.15%
Guardant Health, Inc.
4.75%
Illumina, Inc.
4.75%
Eli Lilly & Co.
4.69%
CareDx, Inc.
4.31%
Natera, Inc.
4.14%
Beam Therapeutics, Inc.
3.78%
Compass Pathways Plc
3.26%
Recursion Pharmaceuticals, Inc.
2.63%
Adaptive Biotechnologies Corp.
2.58%
Frequently asked questions about XBI and ARKG
How have the XBI and ARKG ETFs performed in 2026?
As of September 4, 2026, XBI is up 34.48% year-to-date (YTD), while ARKG has returned 61.37%. That puts ARKG better performer ahead so far this year.
Which ETF is attracting more investor money: XBI or ARKG?
Year-to-date, the XBI ETF saw +$925M in flows, compared to +$141M for ARKG.
Which ETF is more volatile: XBI or ARKG?
Over the past year, XBI had a volatility of 27.9%, while ARKG experienced 44.31%.
Which ETF is bigger: XBI or ARKG?
As of September 4, 2026, XBI holds $11.43 B in assets under management (AUM), while ARKG manages $2.00 B.
What sectors do the XBI and ARKG ETFs invest in?
XBI leans toward sectors like Healthcare. Meanwhile, ARKG focuses on Healthcare.
What are the top holdings of the XBI ETF and ARKG ETF?
XBI top holdings include Apogee Therapeutics, Inc., Oruka Therapeutics, Inc. and Dianthus Therapeutics, Inc.. ARKG holds in its top three: 10X Genomics, Inc., Twist Bioscience Corp. and Tempus AI, Inc..
Which ETF is more diversified: XBI or ARKG?
XBI holds 151 securities with 20.29% of its assets in the top 15. ARKG has 31 securities and a top 15 weight of 75.55%.
Advertisement
Latest news about XBI & ARKG
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
ARKG
Advertisement
Advertisement
